Next Article in Journal
Beyond the Vestibulo-Ocular Reflex: Vestibular Input is Processed Centrally to Achieve Visual Stability
Next Article in Special Issue
Image Stabilization in Central Vision Loss: The Horizontal Vestibulo-Ocular Reflex
Previous Article in Journal
Can Contrast-Response Functions Indicate Visual Processing Levels?
Previous Article in Special Issue
A Retrospective Analysis of the Effect of Subretinal Hyper-Reflective Material and Other Morphological Features of Neovascular Age-Related Macular Degeneration on Visual Acuity Outcomes in Eyes Treated with Intravitreal Aflibercept over One Year
Open AccessReview

New Therapies of Neovascular AMD beyond Anti-VEGF Injections

University of Nevada, Reno School of Medicine, Reno, NV 89557, USA
Sierra Eye Associates, Reno, NV 89502, USA
Author to whom correspondence should be addressed.
Vision 2018, 2(1), 15;
Received: 22 January 2018 / Revised: 4 February 2018 / Accepted: 12 March 2018 / Published: 19 March 2018
(This article belongs to the Special Issue Age-Related Macular Degeneration)
Neovascular age-related macular degeneration is a leading cause of vision loss among the aging population. The current standard of care to treat neovascular age-related macular degeneration is inhibiting vascular endothelial growth factor (VEGF) through intravitreal injections. Recent studies have demonstrated that the tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (Tie2) pathway also plays a critical role in angiogenesis and vascular stability. Additionally, newly developed treatment delivery systems have been designed to greatly reduce the frequency of injections. In targeting the Tie2 pathway and utilizing a sustained release delivery system, patients may experience improved visual outcomes and a reduced burden of treatment. View Full-Text
Keywords: age-related macular degeneration; Tie2; anti-VEGF; RG7716; ranibizumab age-related macular degeneration; Tie2; anti-VEGF; RG7716; ranibizumab
MDPI and ACS Style

Gahn, G.M.; Khanani, A.M. New Therapies of Neovascular AMD beyond Anti-VEGF Injections. Vision 2018, 2, 15.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop